PharmaTher Announces Positive Topline Results from Clinical Study of Ketamine for Parkinson’s Disease
The most common Parkinson’s medication, Levodopa, causes involuntary muscle movements in most patients who take it long-term.
PharmaTher (PHRM) found that a low dose of ketamine reduces these muscle spams in 100% of Parkinson’s patients — but it’s unclear by how much or for how long…
However, a separate study from 2016 found that low doses of ketamine reduced this side effect for up to one month and also eased depression.
PharmaTher is confident that the results will pave the way for a Phase 3 trial.